Delphine REA
APHP, St Louis Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Delphine REA as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:37 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01774630 · Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)University Hospital, Bordeaux · completed · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:37 UTC. The ranking covers the 200 most relevant of 99 PubMed records, and a shared surname and initials can bring in a namesake. All 99 on PubMed
- 1,245 citationsRCR 27.8
- A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.N Engl J Med · 2013903 citationsRCR 24.7
- 492 citationsRCR 18.4
- 428 citationsRCR 8.6
- Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.J Clin Oncol · 2008407 citationsRCR 9.1
- 402 citationsRCR 8.2
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.N Engl J Med · 2019376 citationsRCR 13.6
- Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.Lancet Oncol · 2020314 citationsRCR 11.6
- Addressing overtreatment of screen detected DCIS; the LORIS trial.Eur J Cancer · 2015313 citationsRCR 10.0
- Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.N Engl J Med · 2010305 citationsRCR 6.8